CA2644566A1 - Cancer treatments - Google Patents
Cancer treatments Download PDFInfo
- Publication number
- CA2644566A1 CA2644566A1 CA002644566A CA2644566A CA2644566A1 CA 2644566 A1 CA2644566 A1 CA 2644566A1 CA 002644566 A CA002644566 A CA 002644566A CA 2644566 A CA2644566 A CA 2644566A CA 2644566 A1 CA2644566 A1 CA 2644566A1
- Authority
- CA
- Canada
- Prior art keywords
- oxaliplatin
- liposome
- cancer
- cisplatin
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 85
- 238000011282 treatment Methods 0.000 title claims abstract description 84
- 201000011510 cancer Diseases 0.000 title claims abstract description 39
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims abstract description 394
- 229960001756 oxaliplatin Drugs 0.000 claims abstract description 370
- 239000002502 liposome Substances 0.000 claims abstract description 135
- 238000000034 method Methods 0.000 claims abstract description 65
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 20
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims description 91
- 229940079593 drug Drugs 0.000 claims description 84
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 67
- 229960004316 cisplatin Drugs 0.000 claims description 66
- 229960005277 gemcitabine Drugs 0.000 claims description 57
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 56
- -1 phosphatidyl glycerol lipid Chemical class 0.000 claims description 38
- 238000001802 infusion Methods 0.000 claims description 36
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 33
- 150000002632 lipids Chemical class 0.000 claims description 33
- 239000000693 micelle Substances 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 22
- 239000003446 ligand Substances 0.000 claims description 21
- 238000002648 combination therapy Methods 0.000 claims description 18
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 15
- 239000002245 particle Substances 0.000 claims description 15
- 229920000642 polymer Polymers 0.000 claims description 15
- 206010009944 Colon cancer Diseases 0.000 claims description 14
- 230000001093 anti-cancer Effects 0.000 claims description 14
- 102400001047 Endostatin Human genes 0.000 claims description 13
- 108010079505 Endostatins Proteins 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 12
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 12
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 229960004679 doxorubicin Drugs 0.000 claims description 11
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 11
- 201000002528 pancreatic cancer Diseases 0.000 claims description 11
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- 210000004072 lung Anatomy 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 10
- 230000003442 weekly effect Effects 0.000 claims description 10
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 229960003668 docetaxel Drugs 0.000 claims description 9
- 238000001990 intravenous administration Methods 0.000 claims description 9
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 9
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 229930012538 Paclitaxel Natural products 0.000 claims description 8
- 229960001592 paclitaxel Drugs 0.000 claims description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 8
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 7
- 210000000481 breast Anatomy 0.000 claims description 7
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 7
- 229960000961 floxuridine Drugs 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 7
- 230000002496 gastric effect Effects 0.000 claims description 6
- 239000001294 propane Substances 0.000 claims description 6
- 102400000068 Angiostatin Human genes 0.000 claims description 5
- 108010079709 Angiostatins Proteins 0.000 claims description 5
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- 230000002381 testicular Effects 0.000 claims description 5
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims description 4
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims description 4
- 102400001368 Epidermal growth factor Human genes 0.000 claims description 4
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 229940116977 epidermal growth factor Drugs 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 4
- 102400001212 Anastellin Human genes 0.000 claims description 3
- 101800002812 Anastellin Proteins 0.000 claims description 3
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 101800000990 PEX Proteins 0.000 claims description 3
- 102100035153 Phosphate-regulating neutral endopeptidase PHEX Human genes 0.000 claims description 3
- 150000003863 ammonium salts Chemical class 0.000 claims description 3
- 239000004019 antithrombin Substances 0.000 claims description 3
- IJVMOGKBEVRBPP-ZETCQYMHSA-N dcpg Chemical compound OC(=O)[C@@H](N)C1=CC=C(C(O)=O)C(C(O)=O)=C1 IJVMOGKBEVRBPP-ZETCQYMHSA-N 0.000 claims description 3
- 230000037451 immune surveillance Effects 0.000 claims description 3
- 201000002313 intestinal cancer Diseases 0.000 claims description 3
- 230000002045 lasting effect Effects 0.000 claims description 3
- 229940086322 navelbine Drugs 0.000 claims description 3
- 239000000049 pigment Substances 0.000 claims description 3
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 claims description 3
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 claims description 2
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 2
- 241000282472 Canis lupus familiaris Species 0.000 claims description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 claims description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 2
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 claims description 2
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 claims 7
- 210000003128 head Anatomy 0.000 claims 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 180
- 229910052697 platinum Inorganic materials 0.000 description 74
- 210000001519 tissue Anatomy 0.000 description 69
- 241000700159 Rattus Species 0.000 description 39
- 210000003734 kidney Anatomy 0.000 description 36
- 230000001988 toxicity Effects 0.000 description 32
- 231100000419 toxicity Toxicity 0.000 description 32
- 230000000694 effects Effects 0.000 description 31
- 210000000952 spleen Anatomy 0.000 description 30
- 231100000682 maximum tolerated dose Toxicity 0.000 description 29
- 238000002347 injection Methods 0.000 description 28
- 239000007924 injection Substances 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 26
- 229940090044 injection Drugs 0.000 description 26
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 24
- 238000007912 intraperitoneal administration Methods 0.000 description 24
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 22
- 210000004185 liver Anatomy 0.000 description 21
- 230000004044 response Effects 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 201000010099 disease Diseases 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 18
- 230000009467 reduction Effects 0.000 description 17
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 206010029350 Neurotoxicity Diseases 0.000 description 14
- 206010044221 Toxic encephalopathy Diseases 0.000 description 14
- 230000008901 benefit Effects 0.000 description 14
- 231100000228 neurotoxicity Toxicity 0.000 description 14
- 230000007135 neurotoxicity Effects 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 229940109239 creatinine Drugs 0.000 description 11
- 230000003902 lesion Effects 0.000 description 11
- 210000000265 leukocyte Anatomy 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 238000002512 chemotherapy Methods 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 231100000417 nephrotoxicity Toxicity 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 9
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 9
- 210000001772 blood platelet Anatomy 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 208000004235 neutropenia Diseases 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 229940116269 uric acid Drugs 0.000 description 9
- 206010029155 Nephropathy toxic Diseases 0.000 description 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 239000004202 carbamide Substances 0.000 description 8
- 238000002591 computed tomography Methods 0.000 description 8
- 238000005538 encapsulation Methods 0.000 description 8
- 230000007694 nephrotoxicity Effects 0.000 description 8
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 7
- 206010061818 Disease progression Diseases 0.000 description 7
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 7
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 108010054147 Hemoglobins Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 7
- 230000005750 disease progression Effects 0.000 description 7
- 229960002949 fluorouracil Drugs 0.000 description 7
- 239000011672 folinic acid Substances 0.000 description 7
- 229960001691 leucovorin Drugs 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 206010067484 Adverse reaction Diseases 0.000 description 6
- 230000006838 adverse reaction Effects 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 230000008034 disappearance Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 230000002489 hematologic effect Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 206010028813 Nausea Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 238000004820 blood count Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 235000008191 folinic acid Nutrition 0.000 description 5
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229960004768 irinotecan Drugs 0.000 description 5
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 230000008693 nausea Effects 0.000 description 5
- 230000002611 ovarian Effects 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 210000005084 renal tissue Anatomy 0.000 description 5
- 231100000440 toxicity profile Toxicity 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 4
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 206010027452 Metastases to bone Diseases 0.000 description 4
- 206010027457 Metastases to liver Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 102000006815 folate receptor Human genes 0.000 description 4
- 108020005243 folate receptor Proteins 0.000 description 4
- 230000000799 fusogenic effect Effects 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 231100000226 haematotoxicity Toxicity 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 3
- 208000002633 Febrile Neutropenia Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 3
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 230000003474 anti-emetic effect Effects 0.000 description 3
- 239000002111 antiemetic agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- 190000008236 carboplatin Chemical compound 0.000 description 3
- 238000011976 chest X-ray Methods 0.000 description 3
- YMHQVDAATAEZLO-UHFFFAOYSA-N cyclohexane-1,1-diamine Chemical compound NC1(N)CCCCC1 YMHQVDAATAEZLO-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 231100001231 less toxic Toxicity 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 208000037821 progressive disease Diseases 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 210000004916 vomit Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 102400001048 Non-collagenous domain 1 Human genes 0.000 description 2
- 101800000353 Non-collagenous domain 1 Proteins 0.000 description 2
- 206010033109 Ototoxicity Diseases 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000002938 Thrombospondin Human genes 0.000 description 2
- 108060008245 Thrombospondin Proteins 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 229940125683 antiemetic agent Drugs 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000007469 bone scintigraphy Methods 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 231100000262 ototoxicity Toxicity 0.000 description 2
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 2
- 108010044644 pegfilgrastim Proteins 0.000 description 2
- 229960001373 pegfilgrastim Drugs 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000011255 standard chemotherapy Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 230000004572 zinc-binding Effects 0.000 description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical class CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
- BUJCVBRLTBAYCW-UHFFFAOYSA-N 3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-2-(2-methoxyphenoxy)propan-1-one Chemical compound COC1=CC=CC=C1OC(CO)C(=O)C1=CC=C(O)C(OC)=C1 BUJCVBRLTBAYCW-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- YNCHFVRXEQFPBY-BQBZGAKWSA-N Asp-Gly-Arg Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N YNCHFVRXEQFPBY-BQBZGAKWSA-N 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108010001463 Collagen Type XVIII Proteins 0.000 description 1
- 102000047200 Collagen Type XVIII Human genes 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 description 1
- 102100022474 DNA repair protein complementing XP-A cells Human genes 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229920006063 Lamide® Polymers 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102000037602 Platelet Endothelial Cell Adhesion Molecule-1 Human genes 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- NIGUVXFURDGQKZ-UQTBNESHSA-N alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O NIGUVXFURDGQKZ-UQTBNESHSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 229920006187 aquazol Polymers 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001876 chaperonelike Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 231100000026 common toxicity Toxicity 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 229940093541 dicetylphosphate Drugs 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 229940020967 gemzar Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000052 myelotoxic Toxicity 0.000 description 1
- 230000002556 myelotoxic effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000025440 neoplasm of neck Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100001092 no hepatotoxicity Toxicity 0.000 description 1
- 231100001095 no nephrotoxicity Toxicity 0.000 description 1
- 231100001096 no neurotoxicity Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 230000020520 nucleotide-excision repair Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940104914 oxaliplatin injection Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- XLMFDCKSFJWJTP-UHFFFAOYSA-N pentane-2,3-diol Chemical compound CCC(O)C(C)O XLMFDCKSFJWJTP-UHFFFAOYSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20060100144A GR20060100144A (el) | 2006-03-03 | 2006-03-03 | Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene |
| GR20060100144 | 2006-03-03 | ||
| PCT/GR2007/000015 WO2007099377A2 (en) | 2006-03-03 | 2007-03-05 | Cancer treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2644566A1 true CA2644566A1 (en) | 2007-09-07 |
Family
ID=38325437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002644566A Abandoned CA2644566A1 (en) | 2006-03-03 | 2007-03-05 | Cancer treatments |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20090053302A1 (enExample) |
| EP (1) | EP2001441A2 (enExample) |
| JP (1) | JP2009528340A (enExample) |
| KR (1) | KR20090023548A (enExample) |
| CN (1) | CN101522172A (enExample) |
| AU (1) | AU2007220263A1 (enExample) |
| BR (1) | BRPI0707059A2 (enExample) |
| CA (1) | CA2644566A1 (enExample) |
| EA (1) | EA200801912A1 (enExample) |
| GR (1) | GR20060100144A (enExample) |
| MA (1) | MA30314B1 (enExample) |
| MX (1) | MX2008011263A (enExample) |
| NO (1) | NO20083927L (enExample) |
| RS (1) | RS20080388A (enExample) |
| TN (1) | TNSN08345A1 (enExample) |
| WO (1) | WO2007099377A2 (enExample) |
| ZA (1) | ZA200807934B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9186322B2 (en) * | 2002-08-02 | 2015-11-17 | Insmed Incorporated | Platinum aggregates and process for producing the same |
| US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
| KR20080094473A (ko) * | 2007-04-20 | 2008-10-23 | 한국화학연구원 | 음이온성 지질나노입자 및 이의 제조방법 |
| ES2465477T3 (es) * | 2008-01-28 | 2014-06-05 | Nanocarrier Co., Ltd. | Composición farmacéutica y fármaco combinado |
| TWI468188B (zh) * | 2008-01-30 | 2015-01-11 | Univ Tokushima | Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation |
| EP2259844A4 (en) * | 2008-03-05 | 2012-02-01 | Vicus Therapeutics Llc | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGICAL THERAPIES |
| EP2123258A1 (en) * | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes for drug delivery |
| WO2010138550A1 (en) * | 2009-05-27 | 2010-12-02 | Northeastern University | Conjugated nanodelivery vehicles |
| AU2010296180B2 (en) * | 2009-09-21 | 2016-05-05 | Bio-Synectics, Inc | Oxaliplatin nanoparticles and method for preparing same |
| JP5817053B2 (ja) * | 2010-04-02 | 2015-11-18 | 国立大学法人 千葉大学 | 腫瘍特異性を有するリポソーム |
| CN102133176B (zh) * | 2011-03-22 | 2012-09-05 | 济南宏瑞创博医药科技开发有限公司 | 一种奥沙利铂胶束制剂及其制备方法及应用 |
| JP5378469B2 (ja) | 2011-08-11 | 2013-12-25 | 学校法人 日本歯科大学 | 医療用薬剤 |
| SG10201701063WA (en) * | 2012-08-10 | 2017-04-27 | Taiho Pharmaceutical Co Ltd | Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same |
| MA37931A1 (fr) * | 2012-08-13 | 2016-07-29 | Teni Boulikas | Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduite |
| KR20150044838A (ko) * | 2012-08-13 | 2015-04-27 | 레귤론, 인코퍼레이티드. | 리포플라틴을 이용한 암 치료방법 |
| EP2892524B1 (en) | 2012-09-04 | 2020-11-25 | Eleison Pharmaceuticals, LLC | Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin |
| EA023757B1 (ru) * | 2012-12-24 | 2016-07-29 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Способ получения липосомальной формы оксалиплатина |
| EP2968144A1 (en) * | 2013-03-13 | 2016-01-20 | Mallinckrodt LLC | Liposome oxaliplatin compositions for cancer therapy |
| UA117581C2 (uk) * | 2013-03-27 | 2018-08-27 | Тайхо Фармасьютікал Ко., Лтд. | Протипухлинний лікарський засіб, який включає низькодозований гідрохлориду іринотекану гідрат |
| CN103622912B (zh) * | 2013-12-05 | 2016-02-24 | 常州金远药业制造有限公司 | 盐酸多柔比星-多西他赛或紫杉醇脂质体制剂及其制备方法 |
| CA2976526A1 (en) * | 2015-02-13 | 2016-08-18 | Trendmed Co., Ltd. | Compositions and methods of tumor treatment utilizing nanoparticles |
| WO2016141161A1 (en) | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Dual loaded liposomal pharmaceutical formulations |
| WO2016141167A1 (en) | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Combination liposomal pharmaceutical formulations |
| KR101687735B1 (ko) * | 2015-09-18 | 2016-12-19 | 서울대학교 산학협력단 | 신규의 동결건조보조제 및 새로운 인지질 용해용 혼합용매를 이용한 리포좀 동결분체의 제조방법 |
| WO2017192502A1 (en) * | 2016-05-03 | 2017-11-09 | The American University In Cairo | Liposomal delivery systems for oxaliplatin and in dual drug delivery in combination with chemo-sensitizing and chemo-therapeutic agents |
| US10940112B2 (en) | 2016-05-04 | 2021-03-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
| CN106074379B (zh) * | 2016-07-11 | 2019-01-25 | 中国科学院上海药物研究所 | 聚乙二醇化奥沙利铂前药及其制备方法和用途 |
| CN112656764B (zh) * | 2020-12-28 | 2022-09-02 | 吉林大学 | 一种紫杉醇铂类共载靶向长循环脂质体及应用 |
| CN114814023B (zh) * | 2022-04-24 | 2024-07-30 | 江苏省中医院 | 脂质分子在作为胃癌化疗药耐药的预测性标志物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2046997C (en) * | 1990-07-16 | 2000-12-12 | Hiroshi Kikuchi | Liposomal products |
| US6060080A (en) * | 1990-07-16 | 2000-05-09 | Daiichi Pharmaceutical Co., Ltd. | Liposomal products |
| US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| CN1254234C (zh) * | 2000-06-09 | 2006-05-03 | 莱古伦公司 | 质粒dna(lipogenestm)和含细胞核定位信号/促融合肽缀合物的治疗剂包封到定向脂质体复合体中 |
| CA2383259A1 (en) * | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| US20040022842A1 (en) * | 2002-06-03 | 2004-02-05 | Mebiopharm Co., Ltd. | Liposome preparations containing oxaliplatin |
| JP3415131B1 (ja) * | 2002-06-03 | 2003-06-09 | メビオファーム株式会社 | リポソーム製剤 |
| EP1545459A4 (en) * | 2002-08-02 | 2007-08-22 | Transave Inc | PLATINUM AGGREGATES, AND METHOD FOR MANUFACTURING THE SAME |
| AU2004235781A1 (en) * | 2003-05-02 | 2004-11-18 | Aronex Pharmaceuticals, Inc. | Lipid platinum complexes and methods of use thereof |
| WO2005000266A2 (en) * | 2003-05-22 | 2005-01-06 | Neopharm, Inc. | Liposomal formulations comprising a combination of two or more active agents |
-
2006
- 2006-03-03 GR GR20060100144A patent/GR20060100144A/el not_active IP Right Cessation
-
2007
- 2007-03-05 EA EA200801912A patent/EA200801912A1/ru unknown
- 2007-03-05 MX MX2008011263A patent/MX2008011263A/es not_active Application Discontinuation
- 2007-03-05 RS RSP-2008/0388A patent/RS20080388A/sr unknown
- 2007-03-05 AU AU2007220263A patent/AU2007220263A1/en not_active Abandoned
- 2007-03-05 CA CA002644566A patent/CA2644566A1/en not_active Abandoned
- 2007-03-05 EP EP07712997A patent/EP2001441A2/en not_active Withdrawn
- 2007-03-05 BR BRPI0707059-4A patent/BRPI0707059A2/pt not_active IP Right Cessation
- 2007-03-05 CN CNA2007800139281A patent/CN101522172A/zh active Pending
- 2007-03-05 WO PCT/GR2007/000015 patent/WO2007099377A2/en not_active Ceased
- 2007-03-05 US US12/281,541 patent/US20090053302A1/en not_active Abandoned
- 2007-03-05 KR KR1020087024248A patent/KR20090023548A/ko not_active Ceased
- 2007-03-05 JP JP2008556861A patent/JP2009528340A/ja active Pending
-
2008
- 2008-09-02 MA MA31204A patent/MA30314B1/fr unknown
- 2008-09-03 TN TNP2008000345A patent/TNSN08345A1/en unknown
- 2008-09-15 NO NO20083927A patent/NO20083927L/no not_active Application Discontinuation
- 2008-09-16 ZA ZA200807934A patent/ZA200807934B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA30314B1 (fr) | 2009-04-01 |
| MX2008011263A (es) | 2008-12-12 |
| ZA200807934B (en) | 2009-11-25 |
| BRPI0707059A2 (pt) | 2011-04-19 |
| AU2007220263A1 (en) | 2007-09-07 |
| EA200801912A1 (ru) | 2009-02-27 |
| JP2009528340A (ja) | 2009-08-06 |
| RS20080388A (sr) | 2009-07-15 |
| WO2007099377A2 (en) | 2007-09-07 |
| GR20060100144A (el) | 2007-10-17 |
| EP2001441A2 (en) | 2008-12-17 |
| TNSN08345A1 (en) | 2009-12-29 |
| CN101522172A (zh) | 2009-09-02 |
| US20090053302A1 (en) | 2009-02-26 |
| KR20090023548A (ko) | 2009-03-05 |
| WO2007099377A3 (en) | 2008-04-17 |
| NO20083927L (no) | 2008-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090053302A1 (en) | Cancer treatments | |
| Pillai | Nanotechnology toward treating cancer: A comprehensive review | |
| Khan et al. | Methotrexate: a detailed review on drug delivery and clinical aspects | |
| US7311924B2 (en) | Compositions and methods for treating cancer | |
| Lu et al. | Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer | |
| CN108366965B (zh) | 稳定喜树碱药物组合物 | |
| US20060269542A1 (en) | Immunoliposome composition for targeting to a HER2 cell receptor | |
| Marzban et al. | Optimizing the therapeutic efficacy of cisplatin PEGylated liposomes via incorporation of different DPPG ratios: In vitro and in vivo studies | |
| Liu et al. | Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent | |
| CA2700810A1 (en) | Immunoliposomes for treatment of cancer | |
| JP2015071631A (ja) | リンパ腫の治療のための組成物および方法 | |
| US20240041769A1 (en) | Compositions and methods for delivery of anticancer agents with improved therapeutic index | |
| WO2008038291A1 (en) | Combination of liposomal anti-cancer drugs and lysosome/endosome ph increasing agents for therapy | |
| CN115605196A (zh) | 用于治疗癌症和癌症耐药性的脂质体制剂 | |
| Webb et al. | In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine | |
| US20250064784A1 (en) | Liposome composition comprising liposomal prodrug of mitomycin c and methods of treatment | |
| EP4110347A1 (en) | Composition and method to prepare long-acting injectable suspension containing multiple cancer drugs | |
| US10925831B2 (en) | Liposomal formulations of platinum-acridine anticancer agents and methods thereof | |
| US20070292497A1 (en) | Method for treating micrometastatic tumors | |
| US20240398725A1 (en) | Nanoparticles for cancer treatment | |
| US20200390702A1 (en) | Liposomal taxanes for treatment of sclc | |
| HK40086650A (zh) | 用於治疗癌症和癌症耐药性的脂质体制剂 | |
| HK40070304A (en) | Stabilizing camptothecin pharmaceutical compositions | |
| Rathi | Development and Characterization of Functionalized Nanoconstructs for Effective Treatment of Lung Cancer | |
| Lewi et al. | Liposomal drug carriers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20140822 |